Profit Guidance Upgrade
Filed with ASX · · 3 pages · English
Summary by 6ix AI
Resonance Health Ltd has announced an upgrade to its profit guidance for the financial year ending in June, reflecting strong operational performance and margin expansion across its business. The company now expects its underlying EBITDA to be significantly higher than previously forecasted, driven by improved cost efficiencies and a focus on higher-margin activities. While revenue expectations have been slightly adjusted downward due to timing issues with a major clinical trial agreement, the overall outlook remains positive with sustained growth anticipated. The announcement highlights the company's strategic focus on clinical trial services and automation to enhance profitability and operational leverage.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Earlier from Resonance Health
- Receipt of R&D Tax Incentive Refund
- Half Year Results Presentation
- Half Year Results
- Half Year Report & Accounts
- Quarterly Activities/Appendix 4C Cash Flow Report
Later from Resonance Health
- Liver Fibrosis Device Progress & FY26 Portfolio Webinar
- Cessation of Quarterly Reporting
- FY26 Full Year Results Webinar
- Appendix 4E, Full Year Statutory Accounts & Annual Report
- FY26 Full Year Results & FY27 Guidance Investor Presentation
Follow Resonance Health into a list and get an email when it puts out news.
Follow Resonance Health